1. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anticarcinogenic mechanisms. Arch Biochem Biophys. 2009;486(2):95–102.
2. Kulkarni SS, Canto C. The molecular targets of resveratrol. Biochim Biophys Acta. 2015;1852(6):1114–1123.
3. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived
from grapes. Science. 1997;275(5297):218–220.
4. Hadi SM, Asad SF, Singh S, Ahmad A. Putative mechanism for anticancer and apoptosis-inducing properties
of plant-derived polyphenolic compounds. IUBMB life. 2000;50(3):167–171.
5. Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18(1):33–50.
6. Edsall LC, Van Brocklyn JR, Cuvillier O, Kleuser B, Spiegel S. N,N-Dimethylsphingosine is a potent
competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of
sphingosine 1-phosphate and ceramide. Biochemistry. 1998;37(37):12892–12898.
7. Mizutani N, Omori Y, Kawamoto Y, et al. Resveratrol-induced transcriptional up-regulation of ASMase
(SMPD1) of human leukemia and cancer cells. Biochem Biophys Res Commun. 2016;470(4):851–856.
8. Ito T, Akao Y, Yi H, et al. Antitumor effect of resveratrol oligomers against human cancer cell lines and
the molecular mechanism of apoptosis induced by vaticanol C. Carcinogenesis. 2003;24(9):1489–1497.
9. Nishida Y, Mizutani N, Inoue M, et al. Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA ligase
IV transcription of daunorubicin-resistant leukemia cell lines. Biochim Biophys Acta. 2014;1839(4):265–274.
10. Sobue S, Mizutani N, Aoyama Y, et al. Mechanism of paclitaxel resistance in a human prostate cancer cell
line, PC3-PR, and its sensitization by cabazitaxel. Biochem Biophys Res Commun. 2016;479(4):808–813.
11. Inoue C, Sobue S, Aoyama Y, et al. BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic
cytotoxicity against imatinib-resistant Ph+ ALL cells. Biochem Biophys Rep. 2018;15:69–75.
12. Sobue S, Nemoto S, Murakami M, et al. Implications of sphingosine kinase 1 expression level for the
cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells. Int J
Hematol. 2008;87(3):266–275.
13. Triola G, Fabrias G, Casas J, Llebaria A. Synthesis of cyclopropene analogues of ceramide and their effect
on dihydroceramide desaturase. J Org Chem. 2003;68(26):9924–9932.
14. Ito H, Murakami M, Furuhata A, et al. Transcriptional regulation of neutral sphingomyelinase 2 gene
expression of a human breast cancer cell line, MCF-7, induced by the anti-cancer drug, daunorubicin.
Biochim Biophys Acta. 2009;1789(11-12):681–690.
15. Furuhata A, Kimura A, Shide K, et al. p27 deregulation by Skp2 overexpression induced by the JAK2V617
mutation. Biochem Biophys Res Commun. 2009;383(4):411–416.
16. Sobue S, Iwasaki T, Sugisaki C, et al. Quantitative RT-PCR analysis of sphingolipid metabolic enzymes in
acute leukemia and myelodysplastic syndromes. Leukemia. 2006;20(11):2042–2046.
17. Tanaka K, Tamiya-Koizumi K, Hagiwara K, et al. Role of down-regulated neutral ceramidase during
all-trans retinoic acid-induced neuronal differentiation in SH-SY5Y neuroblastoma cells. J Biochem.
2012;151(6):611–620.
18. Kasumov T, Huang H, Chung YM, Zhang R, McCullough AJ, Kirwan JP. Quantification of ceramide
species in biological samples by liquid chromatography electrospray ionization tandem mass spectrometry.
Anal Biochem. 2010;401(1):154–161.
19. Nakanishi H, Ogiso H, Taguchi R. Qualitative and quantitative analyses of phospholipids by LC-MS for
lipidomics. Methods Mol Biol. 2009;579:287–313.
20. Bernardo K, Hurwitz R, Zenk T, et al. Purification, characterization, and biosynthesis of human acid
ceramidase. J Biol Chem. 1995;270(19):11098–11102.
279
VTC-induced apoptosis and sphingolipid
21. Yun JM, Chien A, Jialal I, Devaraj S. Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress
in the diabetic milieu: mechanistic insights. J Nutr Biochem. 2012;23(7):699–705.
22. Baran Y, Bielawski J, Gunduz U, Ogretmen B. Targeting glucosylceramide synthase sensitizes imatinibresistant chronic myeloid leukemia cells via endogenous ceramide accumulation. J Cancer Res Clin Oncol.
2011;137(10):1535–1544.
23. Triola G, Fabrias G, Dragusin M, et al. Specificity of the dihydroceramide desaturase inhibitor N-[(1R,2S)2-hydroxy-1-hydroxymethyl-2-(2-tridecyl-1-cyclopropenyl)ethyl]octanami de (GT11) in primary cultured
cerebellar neurons. Mol Pharmacol. 2004;66(6):1671–1678.
24. McNaughton M, Pitman M, Pitson SM, Pyne NJ, Pyne S. Proteasomal degradation of sphingosine
kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or
ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells. Oncotarget.
2016;7(13):16663–16675.
25. Fukui M, Yamabe N, Zhu BT. Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast
cancer cells in vitro and in vivo. Eur J Cancer. 2010;46(10):1882–1891.
26. Mondal A, Bennett LL. Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast
cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage. Biomed Pharmacother.
2016;84:1906–1914.
27. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov.
2006;5(6):493–506.
28. Wightman EL, Reay JL, Haskell CF, Williamson G, Dew TP, Kennedy DO. Effects of resveratrol alone or in
combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects:
a randomised, double-blind, placebo-controlled, cross-over investigation. Br J Nutr. 2014;112(2):203–213.
29. Colin D, Gimazane A, Lizard G, et al. Effects of resveratrol analogs on cell cycle progression, cell
cycle associated proteins and 5fluoro-uracil sensitivity in human derived colon cancer cells. Int J Cancer.
2009;124(12):2780–2788.
30. Lim KG, Gray AI, Pyne S, Pyne NJ. Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect
sphingosine kinase 1 expression and cancer cell growth and survival. Br J Pharmacol. 2012;166(5):1605–
1616.
31. Zhu Q, Yang J, Zhu R, et al. Dihydroceramide-desaturase-1-mediated caspase 9 activation through ceramide
plays a pivotal role in palmitic acid-induced HepG2 cell apoptosis. Apoptosis. 2016;21(9):1033–1044.
32. Siddique MM, Bikman BT, Wang L, et al. Ablation of dihydroceramide desaturase confers resistance to
etoposide-induced apoptosis in vitro. PLoS One. 2012;7(9):e44042.
33. Casasampere M, Ordonez YF, Pou A, Casas J. Inhibitors of dihydroceramide desaturase 1: therapeutic agents
and pharmacological tools to decipher the role of dihydroceramides in cell biology. Chem Phys Lipids.
2016;197:33–44.
34. Zhang Y, Wang Y, Wan Z, Liu S, Cao Y, Zeng Z. Sphingosine kinase 1 and cancer: a systematic review
and meta-analysis. PLoS One. 2014;9(2):e90362.
35. Gouaze V, Liu YY, Prickett CS, Yu JY, Giuliano AE, Cabot MC. Glucosylceramide synthase blockade
down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs.
Cancer Res. 2005;65(9):3861–3867.
36. Li QF, Huang WR, Duan HF, Wang H, Wu CT, Wang LS. Sphingosine kinase-1 mediates BCR/ABL-induced
upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene. 2007;26(57):7904–7908.
37. Salas A, Ponnusamy S, Senkal CE, et al. Sphingosine kinase-1 and sphingosine 1-phosphate receptor
2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood.
2011;117(22):5941–5952.
38. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC. Accumulation of glucosylceramides in multidrugresistant cancer cells. J Biol Chem. 1996;271(32):19530–19536.
39. Itoh M, Kitano T, Watanabe M, et al. Possible role of ceramide as an indicator of chemoresistance:
decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase
in chemoresistant leukemia. Clin Cancer Res. 2003;9(1):415–423.
40. Huang WC, Tsai CC, Chen CL, et al. Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid
leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated
apoptosis. FASEB J. 2011;25(10):3661–3673.
41. Igarashi N, Okada T, Hayashi S, Fujita T, Jahangeer S, Nakamura S. Sphingosine kinase 2 is a nuclear
protein and inhibits DNA synthesis. J Biol Chem. 2003;278(47):46832–46839.
42. White MD, Chan L, Antoon JW, Beckman BS. Targeting ovarian cancer and chemoresistance through
selective inhibition of sphingosine kinase-2 with ABC294640. Anticancer Res. 2013;33(9):3573–3579.
280
Chisato Inoue et al
43. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S, Aggarwal BB. Piceatannol inhibits
TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of
IkappaBalpha kinase and p65 phosphorylation. J Immunol. 2002;169(11):6490–6497.
...
論文の公開元へ
